PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE

100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.

Evidence

MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX

Source: San Antonio Breast Cancer Symposiumยฎ Authors: Joyce Oโ€™Shaughnessy, Priyanka Sharma, Cynthia R C Osborne, Gregory Vidal, Pond Remsen Kelemen, Suzanne Hoekstra, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, FLEX Investigatorsโ€™ Group Title: MammaPrintยฎ and BluePrintยฎ Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Read More

Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data

Source:ย  San Antonio Breast Cancer Symposiumยฎ Authors: Adam Brufsky*, Kent Hoskins, Henry Conter, Pond Kelemen, Mehran Habibi, Laila Samian, Robert Maganini, Rakshanda Rahman, Laura Lee, Eduardo Dias, Regina Hampton, Beth Seiling, Cynthia Osborne, Eric Brown, Jailan Elayoubi, Priyanka Sharma, Jayanthi Ramadurai, Laurie Matt-Amral, Alfredo Santillan, Sasha Strain, Philip Albaneze, Read More

Association of MammaPrint With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition

Source:ย ย San Antonio Breast Cancer Symposiumยฎ Authors:ย  Adam Brufsky, VK Gadi, Aisha Ahmed, Preethi John, Beth Seiling, Josien Haan6, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce Oโ€™Shaughnessy, FLEX Investigatorsโ€™ Group Title: Association of MammaPrintยฎ With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition Background: Cyclin-dependent kinase Read More

Differential Long-Term Benefit of 2-Year Adjuvant Tamoxifen Therapy for Luminal-Type Breast Cancer: Insights From a 20-Year Follow-Up Analysis of the STO Trials

Publication: ESMO Annals of Oncology, Breast cancer, early stage, Volume 35, Supplement 2S346, September 2024 Authors: M. Rios Romero, O. Danielsson, T. Fornander, A. Nordenskjรถld, G. Pรฉrez Tenorio, N.P. Tobin, B.A. Nordenskjรถld, O. Stรฅl, L. Esserman, L.J. Van't Veer, L.S. Lindstrรถm Title: Differential long-term benefit of 2-year adjuvant tamoxifen Read More

Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial

Publication: JAMA Network Open. 2024;7(11):e2447530. Authors: Laura J. van โ€™t Veer, PhD; Elma Meershoek-Klein Kranenbarg, MS; Marjolijn Duijm-de Carpentier, BS; Cornelis J. H. Van de Velde, MD; Miranda Kleijn, PhD; Christa Dreezen, MS; Andrea R. Menicucci, PhD; William Audeh, MD; Gerrit-Jan Liefers, MD, PhD Title: Selection of Patients With Read More

Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers

Publication: Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1553. Authors: Alejandro Rios-Hoyo, Kaitlyn Xiong, Jiawei Dai, Christina Yau, Michal Marczyk, Rolando Garcia-Milian, Denise M Wolf, Laura A Huppert, Rita Nanda, Gillian L Hirst, Erin F Cobain, Laura J van 't Veer, Laura J Esserman, Lajos Pusztai Title: Hormone Receptor Read More